Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
Ricks also mentioned the potential for expanding the use of these drugs to individuals with a BMI below 25 who are classified as having a healthy weight but are at risk of conditions like diabetes or vascular dementia. He emphasized the need to consider different BMI cut-offs for certain ethnic groups, such as Pacific Islanders, who are known to contract type-two diabetes earlier and at a lower BMI.In a groundbreaking move, Eli Lilly (NYSE:LLY) is set to test its weight-loss medications on individuals who are not overweight but are at risk of gaining weight.
以開創性舉措，伊萊利·(紐交所:LLY)將對非超重但有增重風險的個體進行減重藥物測試。
What Happened: Dave Ricks, CEO of Eli Lilly, announced that the company is considering lowering the BMI threshold for its anti-obesity drugs, Mounjaro and Zepbound. Currently, the BMI cut-off for trials is 27 in the U.S. and northern Europe. Ricks suggested that a BMI of 25 might be more suitable, Financial Times reported on Monday.
發生的事情：伊萊利公司的首席執行官戴夫·瑞克斯宣佈，該公司正在考慮將其抗肥胖藥物Mounjaro和Zepbound的BMI閾值降低。目前，美國和北歐的試驗BMI截止線爲27。瑞克斯建議BMI爲25可能更合適，據《金融時報》週一報道。
Ricks pointed out that trials for Zepbound and the experimental weight-loss pill orforglipron included patients with a BMI of 30 and above, or those with a BMI of 27 and above with weight-related health issues. He argued for lowering the threshold, especially for orforglipron, which results in more modest weight loss.
瑞克斯指出，Zepbound和實驗性減重藥物orforglipron的試驗包括BMI爲30及以上的患者，或BMI爲27及以上且存在與體重有關的健康問題的患者。他主張降低閾值，特別是針對orforglipron，這將導致更爲適中的減重。
Ricks also mentioned the potential for expanding the use of these drugs to individuals with a BMI below 25 who are classified as having a healthy weight but are at risk of conditions like diabetes or vascular dementia. He emphasized the need to consider different BMI cut-offs for certain ethnic groups, such as Pacific Islanders, who are known to contract type-two diabetes earlier and at a lower BMI.
瑞克斯還提到了擴大這些藥物使用範圍的潛力，即針對BMI低於25但被歸類爲健康體重但有患糖尿病或血管性癡呆等疾病風險的個體。他強調需要考慮某些種族群體的不同BMI截止線，比如太平洋島民已知肥胖型糖尿病較早發病且BMI較低。
The demand for Zepbound and Novo Nordisk's Wegovy has led to shortages, prompting both companies to invest heavily in manufacturing capacity. Eli Lilly has discouraged the off-label use of Zepbound for cosmetic purposes, emphasizing the need to prioritize diabetic and obese patients.
對Zepbound和諾洛諾的薇冠(受歡迎的減重藥)的需求導致了短缺，促使兩家公司大力投資製造業-半導體。伊萊利公司反對將Zepbound以化妝品爲目的非規定使用，強調需要優先考慮糖尿病患者和肥胖患者。
Why It Matters: The decision to lower the BMI threshold for weight-loss drug trials comes at a time when Eli Lilly is experiencing significant success in the weight-loss drug market. The company's stock has soared due to the success of its weight-loss medications. However, the company is also facing competition from knockoff drugs, which it claims could be unsafe.
爲什麼重要：在伊萊利在減重藥市場取得巨大成功的同時，降低減重藥試驗的BMI閾值是一個重要決定。由於其減重藥物的成功，公司股票飆升。然而，公司也面臨着仿冒藥物的競爭，公司聲稱這些藥物可能不安全。
Additionally, Eli Lilly stock hit resistance after a significant rally. This indicates that while the company is performing well, it is also navigating market challenges and competition.
此外，伊萊利股票在一個重大漲幅後遇到了支撐位。這表明儘管公司表現良好，但也在應對市場挑戰和競爭。
- Has Medical Marijuana Been Forgotten In Cannabis Reform? 'Its Therapeutic Benefits Are Critical'
- 醫療大麻在大麻改革中被遺忘了嗎？'其療效至關重要'
Photo via Shutterstock
圖片來自shutterstock。
This story was generated using Benzinga Neuro and edited by Pooja Rajkumari
本報道使用Benzinga Neuro生成，並由Pooja Rajkumari編輯
譯文內容由第三人軟體翻譯。
